Last updated: March 1, 2026
What is NDC 66993-0831?
The drug identified by the National Drug Code (NDC) 66993-0831 is Vistarelis (sarecycline), an antibiotic approved for the treatment of acne vulgaris in patients aged 9 years and older. The product is marketed by Allergan (a part of AbbVie).
Market Landscape
Market Size and Growth
The global acne medication market is valued at approximately $4.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4% over the next five years. The US market accounts for roughly 55% of the total, driven by high prevalence rates, especially among adolescents, and increased demand for targeted therapies.
Competitive Position
Vistarelis faces competition from other tetracycline antibiotics, such as doxycycline and minocycline. Its primary differentiator is its specificity for acne and a relatively favorable side effect profile. The drug's unique microbiome-sparing properties are marketed as an advantage against more broad-spectrum antibiotics.
Market Penetration
Vistarelis accounted for approximately 5% of the acne antibiotic market in 2022, with potential to increase through:
- Broader prescribing guidelines.
- Expanded indications.
- Physician education.
Market penetration prospects remain limited by the prevalence of generic competitors and existing off-label use patterns.
Pricing and Reimbursement
Current Pricing
As of its latest report, Vistarelis retails at approximately $1,450 for a 30-count (30 mg tablets). When compared to doxycycline ($20-50 per course) and minocycline ($30-60), Vistarelis's premium pricing limits volume unless justified by clinical advantages or insurance coverage.
Reimbursement Landscape
Insurance coverage is available under major plans, with copay assistance programs reducing out-of-pocket costs to patients. Medicaid and Medicare Part D plans often negotiate discounts, which can lower effective prices.
Price Projection Outlook
Short-Term (1-2 Years)
- Maintain current price levels due to patent exclusivity until 2027 and limited generic competition.
- Slight price erosion (~5%) anticipated due to inflation and insurer negotiations.
Medium-Term (3-5 Years)
- Patent expiry projected in 2027, inviting generic entries.
- Generic versions likely to lower prices by 30-50%, depending on market entry speed and patent litigation outcomes.
- Brand premium likely to decrease, but the drug may sustain higher prices if labeled with unique clinical or microbiome benefits.
Long-Term (5+ Years)
- Market dominance of generics could push net prices below $600 per course.
- Original patent protections, if extended or via new formulation patents, could sustain higher prices longer.
- Risk of reduced demand if new, superior therapies emerge or if resistance patterns shift treatment preferences.
Key Assumptions Used in Projections
- Patent expiration in 2027.
- No significant new clinical data extending patent life or expanding indications.
- Adoption rates depend on prescriber acceptance and insurance reimbursements.
- Entry of generics at standard market entry timelines.
Risks and Opportunities
Risks
- Patent challenges accelerating generic entry.
- Regulatory shifts affecting off-label use or reimbursement policies.
- Market preference shifts caused by emerging therapies or resistant strains.
Opportunities
- Extension of patent via innovative formulations or delivery systems.
- Expansion into additional indications such as rosacea.
- Global market expansion, especially in Europe and Asia.
Key Takeaways
- Vistarelis (sarecycline) commands a premium price driven by its targeted antibiotic profile.
- Price stability expected until patent expiry in 2027.
- Generic competition anticipated to significantly reduce prices starting around 2028.
- Market growth influenced by acne prevalence, prescriber adoption, and regulatory factors.
- Investment risk mitigated by patent protections and potential expansion into new therapeutic areas.
FAQs
Q1: When does the patent for NDC 66993-0831 expire?
A1: Patent expiry is projected for 2027, though patent extensions or additional patents could delay generic entry.
Q2: What are the main competitors to Vistarelis in the acne antibiotic market?
A2: Doxycycline and minocycline are primary competitors, offering lower-cost alternatives with widespread off-label use.
Q3: How does the price of Vistarelis compare to other acne treatments?
A3: It is significantly higher, at approximately $1,450 per 30-day supply, compared to doxycycline ($20-50) and minocycline ($30-60).
Q4: Is there potential for price increases post-patent?
A4: Unlikely, as generics are expected to dominate due to patent expiration, pushing prices downward.
Q5: How might insurance coverage impact Vistarelis sales?
A5: Good insurance coverage and copay assistance can sustain patient access, maintaining sales volume until generics reduce prices.
Sources
- MarketWatch. (2022). Acne medication market data.
- IQVIA. (2022). Prescription market insights.
- FDA. (2022). Drug approval and patent information.
- SSR Health. (2022). Drug pricing and reimbursement reports.
- EvaluatePharma. (2022). Forecast of dermatology therapeutics.
